Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

October 16, 2022

Study Completion Date

June 6, 2024

Conditions
Homozygous Familial Hypercholesterolaemia (HoFH)
Interventions
DRUG

Lomitapide

2mg,5mg, 10mg and 20mg capsules

Trial Locations (12)

5000

E.P.S. Fattouma Bourguiba Hospital, Monastir

15006

Hospital Abente y Lago, A Coruña

20246

University Medical Center Hamburg-Eppendorf, Hamburg

35128

U.O.C. Clinica Medica 1, Padua

43204

Hospital Universitari Sant Joan, Reus

46010

Hospital Clinico Universitario of Valencia, Valencia

50937

University Hospital of Cologne, Cologne

52621

Chaim Sheba Medical Center, Ramat Gan

69120

Universtiats-Kinderlinik Heidelberg, Heidelberg

00165

Bambino Gesù Children's Hospital,, Roma

Unknown

King Abdullah International Medical Research Centre (KAIMRC),, Riyadh

King Faisal Specialist Hospital, Riyadh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amryt Pharma

INDUSTRY